image
Healthcare - Biotechnology - NASDAQ - US
$ 2.15
-1.84 %
$ 11.1 M
Market Cap
-1.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one BCDA stock under the worst case scenario is HIDDEN Compared to the current market price of 2.15 USD, BioCardia, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one BCDA stock under the base case scenario is HIDDEN Compared to the current market price of 2.15 USD, BioCardia, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one BCDA stock under the best case scenario is HIDDEN Compared to the current market price of 2.15 USD, BioCardia, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BCDA

image
$3.2$3.2$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.615 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
58 K REVENUE
-87.84%
-8 M OPERATING INCOME
31.29%
-7.95 M NET INCOME
31.33%
-8.03 M OPERATING CASH FLOW
19.53%
-6 K INVESTING CASH FLOW
50.00%
9.3 M FINANCING CASH FLOW
149.60%
0 REVENUE
100.00%
0 OPERATING INCOME
100.00%
-2.71 M NET INCOME
-18.12%
-1.62 M OPERATING CASH FLOW
37.12%
0 INVESTING CASH FLOW
100.00%
196 K FINANCING CASH FLOW
1206.67%
Balance Sheet BioCardia, Inc.
image
Current Assets 2.62 M
Cash & Short-Term Investments 2.37 M
Receivables 0
Other Current Assets 251 K
Non-Current Assets 1.1 M
Long-Term Investments 0
PP&E 931 K
Other Non-Current Assets 171 K
63.67 %6.74 %25.00 %4.59 %Total Assets$3.7m
Current Liabilities 2.32 M
Accounts Payable 385 K
Short-Term Debt 385 K
Other Current Liabilities 1.55 M
Non-Current Liabilities 566 K
Long-Term Debt 566 K
Other Non-Current Liabilities 0
13.34 %13.34 %53.72 %19.61 %Total Liabilities$2.9m
EFFICIENCY
Earnings Waterfall BioCardia, Inc.
image
Revenue 58 K
Cost Of Revenue 0
Gross Profit 58 K
Operating Expenses 8.06 M
Operating Income -8 M
Other Expenses -55 K
Net Income -7.95 M
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)58k058k(8m)(8m)55k(8m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-13794.83% OPERATING MARGIN
-13794.83%
-13700.00% NET MARGIN
-13700.00%
-949.34% ROE
-949.34%
-213.37% ROA
-213.37%
-447.48% ROIC
-447.48%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis BioCardia, Inc.
image
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -7.95 M
Depreciation & Amortization 67 K
Capital Expenditures -6 K
Stock-Based Compensation 741 K
Change in Working Capital -1.22 M
Others -669 K
Free Cash Flow -8.03 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets BioCardia, Inc.
image
BCDA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership BioCardia, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
6.51 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
1.17 M USD 6
0-3 MONTHS
96.9 K USD 2
3-6 MONTHS
3.08 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia's CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025. globenewswire.com - 3 weeks ago
BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript Start Time: 16:30 January 1, 0000 5:01 PM ET BioCardia, Inc. (NASDAQ:BCDA ) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Company Participants Peter Altman - President and CEO David McClung - CFO Miranda Peto - IR Conference Call Participants Joe Pantginis - H.C. Wainwright Laura Suriel - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. seekingalpha.com - 1 month ago
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. globenewswire.com - 1 month ago
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. globenewswire.com - 1 month ago
Insider Buying Surges in May. Especially These 5 Stocks The Securities Act of 1934 established many of the US rules for the securities market in the aftermath of the 1929 Stock Market Crash that ushered in The Great Depression. 247wallst.com - 1 month ago
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress globenewswire.com - 2 months ago
BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript BioCardia, Inc. (NASDAQ:BCDA ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kumar Raja - Brookline Capital Markets James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. seekingalpha.com - 2 months ago
BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. globenewswire.com - 2 months ago
BioCardia Reports 2024 Business Highlights and Financial Results SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2024 and filed its annual report on Form 10-K with the Securities and Exchange Commission. globenewswire.com - 2 months ago
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2024 on Wednesday, March 26, 2025, and will host a corporate update conference call on Monday, March 31, 2025 (time and dial-information to be announced). The conference call will follow the presentation, “A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial,” at the American College of Cardiology 2025 Scientific Sessions in Chicago on March 30, 2025. globenewswire.com - 2 months ago
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on or after September 30, 2034. globenewswire.com - 3 months ago
BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions SUNNYVALE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the completion of source data verification and freezing of primary outcomes data in the double-blind randomized placebo-controlled Phase 3 CardiAMP HF study of its autologous minimally invasive cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF). Data from the 115 randomized patients in the study has been transferred to the Statistical Data Analysis Center core laboratory for analysis. Results are scheduled to be presented at the Late-Breaking Clinical Trials symposium at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago on March 30, 2025. globenewswire.com - 3 months ago
8. Profile Summary

BioCardia, Inc. BCDA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 11.1 M
Dividend Yield 0.00%
Description BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Contact 320 Soquel Way, Sunnyvale, CA, 94085 https://www.biocardia.com
IPO Date Nov. 13, 1996
Employees 17
Officers Mr. Edward M. Gillis Senior Vice President of Devices Mr. David McClung Chief Financial Officer Dr. Peter A. Altman Ph.D. Chief Executive Officer, President & Director